$MACK News Merrimack Pharma shares surge on licensing

New Post Public Reply Private Reply Replies (0) Message Board

Nov 8, 2014 at 10:59 AM

$MACK News

Merrimack Pharma shares surge on licensing pact with Baxter 6:54 a.m. Sept. 24, 2014 - Tomi Kilgore
Stock futures rise on Bernanke rate comments 4:46 p.m. July 10, 2013 - Wallace Witkowski
Merrimack to offer $50 mln in stock, $75 mln notes 4:24 p.m. July 10, 2013 - MarketWatch.com
Stocks to watch Friday: Goldman, Bally, Scotts 5:54 a.m. Aug. 10, 2012 - MarketWatch
IPO scorecard: Update on selected offering 1:18 p.m. June 8, 2012 - Dow Jones
Shares of Merrimack Pharmaceuticals off post IPO 2:19 a.m. March 30, 2012 - MarketWatch.com

Will Inovio (INO) Disappoint Expectations for Q3 Earnings? - Analyst Blog 4:35 p.m. Nov. 7, 2014 - Zacks.com
Can Merrimack (MACK) Keep the Earnings Streak Alive in Q3? - Analyst Blog 4:30 p.m. Nov. 7, 2014 - Zacks.com
Will Intercept Pharmaceuticals' (ICPT) Q3 Loss Narrow? - Analyst Blog 4:02 p.m. Nov. 6, 2014 - Zacks.com
What's in Store for TrovaGene (TROV) This Earnings Season? - Analyst Blog 3:40 p.m. Nov. 5, 2014 - Zacks.com
Merrimack cancer candidate tagged an Orphan Drug 11:26 a.m. Nov. 5, 2014 - Seeking Alpha
Is a Surprise Coming for Merrimack Pharmaceuticals (MACK) This Earnings Season? - Tale of the Tape 8:36 a.m. Nov. 5, 2014 - Zacks.com
Will Humana (HUM) Miss on Earnings Estimates this Season? - Analyst Blog 3:50 p.m. Nov. 4, 2014 - Zacks.com
Prosensa Holding N.V. (RNA) Jumps: Stock Moves Up 9.9% - Tale of the Tape 9:39 a.m. Nov. 3, 2014 - Zacks.com
Alder Biopharmaceuticals (ALDR) Jumps: Stock Rises 6.5% - Tale of the Tape 8:51 a.m. Nov. 3, 2014 - Zacks.com
Oncolytics Biotech (ONCY) Looks Strong: Stock Up 21.9% - Tale of the Tape 8:44 a.m. Nov. 3, 2014 - Zacks.com
Bristol-Myers Squibb (BMY) Jumps: Stock Moves Up 8.9% - Tale of the Tape 9:39 a.m. Oct. 31, 2014 - Zacks.com
Novo Nordisk A/S (NVO) Shows Strength: Stock Up 6.2% - Tale of the Tape 8:51 a.m. Oct. 31, 2014 - Zacks.com
Cara Therapeutics (CARA) Worth Watching: Stock Rises 6.4% - Tale of the Tape 9:39 a.m. Oct. 30, 2014 - Zacks.com
ANI Pharmaceuticals (ANIP) Shows Strength: Stock Up 6.8% - Tale of the Tape 8:51 a.m. Oct. 30, 2014 - Zacks.com
Baxter Deal Justifies The Potential Of Merrimack's MM-398 12:35 p.m. Oct. 27, 2014 - Seeking Alpha
Verastem (VSTM) Shows Strength: Stock Adds 7% in Session - Tale of the Tape 9:39 a.m. Oct. 27, 2014 - Zacks.com
Merrimack Pharmaceuticals (MACK) Shares March Higher, Can It Continue? - Tale of the Tape 9:07 a.m. Oct. 27, 2014 - Zacks.com
BioMarin Pharmaceutical (BMRN) Jumps: Stock Rises 8% - Tale of the Tape 8:51 a.m. Oct. 27, 2014 - Zacks.com
Biogen Falls on Concerns Regarding Tecfidera Sales and PML Case - Analyst Blog 4:39 p.m. Oct. 24, 2014 - Zacks.com
ZIOPHARM Oncology (ZIOP) Jumps: Stock Moves Up 8.5% - Tale of the Tape 8:51 a.m. Oct. 24, 2014 - Zacks.com

Merrimack Pharmaceuticals Announces Initiation of Phase 1 Clinical Study of MM-398 for Brain Cancer 8:31 a.m. Nov. 6, 2014 - GlobeNewswire
FDA Grants Orphan Drug Designation to Merrimack Pharmaceuticals' MM-141 for the Treatment of Pancreatic Cancer 9:01 a.m. Nov. 5, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Timing of Third Quarter 2014 Investor Conference Call 8:01 a.m. Nov. 3, 2014 - GlobeNewswire
Market Momentum on Biotech Stocks - Amicus Therapeutics, Progenics Pharma, Threshold Pharma, Idera Pharma, and Merrimack Pharma 7:45 a.m. Oct. 22, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Additional Phase 2 Biomarker Data Further Strengthening the Finding That MM-121 Increases Progression Free Survival in Patients With Biomarker Positive Metastatic Breast Cancer 7:00 a.m. Sept. 30, 2014 - GlobeNewswire
PharmaEngine and Merrimack Amend MM-398 License Agreement 3:58 a.m. Sept. 26, 2014 - BusinessWire - BZX
Baxter and Merrimack Pharmaceuticals Enter into Exclusive Ex-U.S. Licensing Agreement to Develop and Commercialize Novel Cancer Compound MM-398 6:00 a.m. Sept. 24, 2014 - BusinessWire - BZX
Merrimack Pharmaceuticals to Present Clinical and Biomarker Data on Novel Antibody Therapeutics at the ESMO 2014 Congress 7:00 a.m. Sept. 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Initiation of HERMIONE, a Randomized Trial of MM-302 in Patients With Advanced HER2-Positive Breast Cancer to Support Application for Accelerated Approval 6:06 a.m. Aug. 11, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Reports Second Quarter 2014 Financial Results 6:01 a.m. Aug. 11, 2014 - GlobeNewswire
Biotech Equities Technical Analysis -- BioMarin Pharma, Merrimack Pharma, Sangamo BioSciences, ZIOPHARM Oncology, and Dyax 7:50 a.m. Aug. 7, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Announces Timing of Second Quarter 2014 Investor Conference Call 3:02 p.m. Aug. 4, 2014 - GlobeNewswire
Divestitures, Agreement for Developmental Rights, Data Presentations, Technical Update, and Licensing Agreements - Analyst Notes on Akorn, Merrimack, Avanir, Omeros and TG Therapeutics 5:40 a.m. June 27, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Data From Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 3:05 p.m. June 25, 2014 - GlobeNewswire
Biotech R&D and Clinical Trials Lead To Potential Revenue Growth - Company's Data of Phase l & Phase ll For HCC Patients Highly Suggestive of Positive Clinical Activity 7:15 a.m. June 25, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals to Regain Worldwide Rights to Develop and Commercialize MM-121 3:15 p.m. June 19, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Announces Oral Presentation of Additional Data Results in Phase 3 NAPOLI-1 Study at the ESMO 16th World Congress on Gastrointestinal Cancer 7:01 a.m. June 17, 2014 - GlobeNewswire
Battle of the Biotech Bands - A Great Time for a Great Cause 1:45 p.m. June 12, 2014 - PR Newswire - PRF
Merrimack Pharmaceuticals Presents Phase 1 Clinical Data Supporting Four Novel Antibody Therapeutic Programs at the 2014 ASCO Annual Meeting 3:00 p.m. June 2, 2014 - GlobeNewswire
Merrimack Pharmaceuticals Identifies Heregulin as Patient Response Biomarker for MM-121 and Standard of Care Therapy Across Multiple Cancers 8:36 a.m. June 2, 2014 - GlobeNewswire

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Travel Smart: Support Wildlife, Avoid Exploitation

Rethink Wildlife Tourism for Ethical Travel You ever stopped to think about what those so-called wildlife attractions are really selling? It’s a feel-good illusion wrapped up in exploitation. Travelers often see animals as part of the backdrop of their holiday stories, but the reality is far from picturesque. Behind the photo ops, there's typically a grim story of...

Graphic Packaging Names Berardinelli as HR Executive

A New Chapter in HR Leadership at Graphic Packaging September 8 marks a turning point for Graphic Packaging Holding Company with the appointment of Tatiana Berardinelli as their new Chief Human Resources Officer. As NYSE:GPK positions itself for ambitious growth, Berardinelli stands out for her knack for managing transformations and building cultures that thrive in...

Aristocrat's Tiki Fire Slots Heat Up North America

The Polynesian Flame Ignites: Tiki Fire Hits Online Games Just when you thought the iGaming world was catching its breath, Aristocrat Interactive throws another curveball. The buzz around their Lightning Link™ series, especially the launch of High Stakes™ in July, took the scene by storm. Now, just in time for another sizzle, they've rolled out Tiki Fire™, bringing...

Finzly Launches AI Security Layer Amid Rising Threats

Bank Security in the Age of AI You'd think banks, of all places, were impenetrable fortresses. But these days, they're more like digital targets. With AI-driven attacks becoming as common as morning coffee, Finzly's introducing Assure, an AI-powered security and assurance layer. It's about as timely as ever, given the 89% spike in AI-enabled attacks seen last year. When...

YSL Beauty’s Block Party Series Rocks London's Scene

YSL Beauty: More Than a Brand, a Cultural Movement London felt a distinct pulse this past weekend as YSL Beauty kicked off another sizzling event in its Block Party series. This one wasn't just another Instagrammable gathering; it was the kind of scene that shifted the cultural needle. What started in Madrid has now become a roving spectacle that sweeps across cities,...

Safety and Wellbeing as Key Business Strategy Focus

Revolutionizing Safety in the Workplace Cracking the typical mindset of treating employee safety as a checkbox item, Debra Wein, CEO and Founder of Wellness Workdays, is set to shake up the NSC Safety Congress & Expo. Her upcoming session, titled "Transforming Safety and Wellbeing into a Competitive Business Advantage," isn't just a run-of-the-mill talk. It's a call to...

Armed Security: Balancing Safety with Cost in Rochester

The Decision to Arm: When Business Risks Demand It You know, deciding whether to hire armed security isn't as clear-cut as some folks make it seem. It ain't just about slapping a guard at your door. There's a whole set of chess moves behind it, especially in good ol' Rochester. When you're juggling high-risk operations, like handling valuable inventory or dealing with...

Nonprofit Option Rises for Specialty Physicians

Reimaging Choices for Specialty Physicians In the whirlwind of healthcare, specialty physicians often find themselves between a rock and a hard place. The traditional paths are either hug a major health system or auction off to private equity, each option chaining them to systems more interested in the balance sheet than in patient care. But now, a third door opens. One...

Curaleaf Eyes Growth: Conference Signals Opportunities

Curaleaf's Strategic Move: Getting in Front of Investors Here comes Curaleaf Holdings, stepping into the spotlight with their eye on increasing investor engagement. Announcing their participation in the ATB Cormark Capital Markets 2026 Fall Institutional Investor Conference, the folks at Curaleaf aren't just talking—they're putting their top brass under the lights. You...

Photronics Faces Legal Heat: Key Investor Steps Now

Eyes on Photronics: A Legal Quake Anytime you hear a stock price nosedive like a kamikaze just blew up its own runway, it ought to set off every investor's alarms. And if you’re tied into Photronics (NASDAQ:PLAB), buddy, it's time to catch up on what's driving this train off the rails. With a class period stretching from December 2025 through May 2026, the dish is a...